There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gossamer Bio (GOSS – Research Report) and Viridian Therapeutics (VRDN – Research Report) with bullish sentiments.
Gossamer Bio (GOSS)
In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on Gossamer Bio, with a price target of $6.00. The company’s shares closed last Monday at $0.85, close to its 52-week low of $0.45.
According to TipRanks.com, Argyrides is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gossamer Bio with a $5.90 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Viridian Therapeutics (VRDN)
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Viridian Therapeutics, with a price target of $36.00. The company’s shares closed last Monday at $21.05.
According to TipRanks.com, Higgins is a 4-star analyst with an average return of
Viridian Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $38.31, a 97.3% upside from current levels. In a report issued on December 4, Wedbush also maintained a Buy rating on the stock with a $37.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GOSS:
